What drove the significant revenue growth in the Companion Animal Group (CAG)?

The substantial revenue increase in the CAG segment was driven by a combination of factors. Strong market demand for companion animal diagnostics globally led to higher sales volumes in recurring diagnostics like IDEXX VetLab consumables and reference laboratory services. Additionally, the segment benefited from a recovery in instrument placements, including the introduction of the new ProCyte One analyzer, compared to the prior year which was impacted by pandemic-related restrictions.

What is the outlook for the LPD (Livestock, Poultry and Dairy) segment, given its recent revenue decline?

The LPD segment experienced a revenue decrease primarily due to lower swine testing volumes in China. This decline is attributed to changes in disease management approaches, low pork prices, and evolving government requirements. Management anticipates these trends will continue to impact LPD revenues in China in upcoming quarters, suggesting a continued challenging outlook for this segment in the near term.

How is IDEXX managing supply chain and logistics challenges?

IDEXX is proactively managing supply chain constraints, including product and component availability and logistics challenges. The company emphasizes building and maintaining a well-managed infrastructure, forward planning, and close collaboration with suppliers and logistics partners. While these challenges are expected to persist, IDEXX believes it is well-positioned to maintain high product and service availability and support its growth plans, though it acknowledges there are no assurances regarding the duration or severity of these issues.

What is the company's liquidity position and cash usage?

IDEXX maintains a strong liquidity position, ending the period with $145.2 million in cash and cash equivalents and $998.6 million in available credit under its revolving credit facility. For the nine months ended September 30, 2021, net cash provided by operating activities was $545.6 million. Significant cash uses included $248.9 million for investing activities (primarily business acquisitions) and $531.6 million for financing activities, the latter largely driven by increased common stock repurchases compared to the prior year.

IDXX 10-Q Quarterly Report Q3 FY2021 — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. reported strong financial results for the nine months ended September 30, 2021, demonstrating robust growth across its key segments. Total revenue increased by 21.6% to $2.41 billion, with organic revenue growth of 18.5% driven by strong performance in the Companion Animal Group (CAG). CAG, the company's largest segment, saw a 23.6% increase in revenue, fueled by strong demand for diagnostic recurring revenue and a significant rebound in instrument placements compared to the pandemic-affected prior year. While the Water segment showed healthy growth, the Livestock, Poultry and Dairy (LPD) segment experienced a decline primarily due to reduced swine testing in China. The company also noted a decrease in revenue from its Other segment, mainly due to lower demand for OPTI COVID-19 PCR testing products. Financially, IDEXX achieved a substantial increase in income from operations, up 43.9% to $732.8 million, and net income grew significantly to $582.1 million. The company maintained a strong balance sheet, ending the period with $145.2 million in cash and cash equivalents and a healthy $998.6 million of availability under its credit facility. Management highlighted continued investments in growth initiatives, including acquisitions such as ezyVet, and indicated confidence in sufficient liquidity to fund operations and future growth. However, the company anticipates ongoing supply chain challenges and potential impacts from global tax reforms.

Financial Highlights

54 data points

Beta

Revenue

$810.42M

0.6% Gross Margin

Net Income

$175.18M

0.2% Net Margin

EPS (Diluted)

$2.03

Total Assets

$2.39B

Cash & Equivalents

$145.20M

Free Cash Flow

$142.19M

Financial Statements

Beta

Revenue	$810.42M
Cost of Revenue	$337.50M
Gross Profit	$472.92M
R&D Expenses	$40.43M
Operating Income	$225.96M
Interest Expense	$7.13M
Net Income	$175.18M
EPS (Basic)	$2.06
EPS (Diluted)	$2.03
Shares Outstanding (Basic)	85.12M
Shares Outstanding (Diluted)	86.51M

Key Highlights

1Total revenue for the nine months ended September 30, 2021, increased by 21.6% to $2.41 billion, with organic revenue growth of 18.5%.
2Companion Animal Group (CAG) revenue grew 23.6% year-over-year, driven by strong demand in recurring diagnostics and a recovery in instrument placements.
3Income from operations surged by 43.9% to $732.8 million, reflecting effective cost management and revenue growth.
4Net income attributable to IDEXX stockholders rose significantly to $582.1 million for the nine-month period.
5The company ended the period with $145.2 million in cash and cash equivalents and $998.6 million in credit facility availability, indicating strong liquidity.
6Acquisitions, including ezyVet, contributed to revenue growth, particularly in the veterinary software and services area.
7The LPD segment experienced a revenue decline of 1.4%, primarily due to reduced swine testing in China.

IDEXX LABORATORIES INC /DE Quarterly Report for Q3 Ended Sep 30, 2021

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions